Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically
revolutionized the therapeutic strategy against advanced malignancies, inspiring the …

Aberrant expression of the programmed cell death protein ligand 1 (PD-L1) constitutes one
of the main immune evasion mechanisms of cancer cells. The approval of drugs against the …

Head and neck squamous cell carcinomas (HNSCC) are characterized by strong cellular
and molecular heterogeneity and treatment resistance entailing poor survival. Besides cell …

Cribriform prostate cancer, found in both invasive cribriform carcinoma (ICC) and intraductal
carcinoma (IDC), is an aggressive histological subtype that is associated with progression to …

Background Preclinical trials of immunotherapy in ovarian cancer (OC) have shown
promising results. This makes it meaningful to prospectively examine the biological …

Metastasis, the chief cause of cancer‐related deaths, is associated with epithelial‐
mesenchymal transition (EMT). In the tumor microenvironment, EMT can be triggered by …

Cancer-associated fibroblasts (CAFs) play a fundamental role in the development of cancers
and their response to therapy. In recent years, CAFs have returned to the spotlight as …

The clinical response to cancer therapies involves the complex interplay between the
systemic, tumoral, and stromal immune response as well as the direct impact of treatments …

Background Prostate cancer (PCa) is the second most diagnosed cancer in men. Most PCa-
related deaths result from metastatic disease. Metastases occur most often in the bones …

Head and neck squamous cell carcinoma (HNSCC) represents one of the most prevalent
and malignant tumors of epithelial origins with unfavorable outcomes. Increasing evidence …